Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Biotechnology

Healthcare
$8.04 +1.97%

+$0.15 today

Market cap
$231.73M
Beta
2.35
P/E (TTM)
-2.7
EPS (TTM)
-$2.77
52W Low $5.85High $24.17

Volume 0.64M

Average 0.43M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$74.27M

FY 2025 · Annual

Investing Cash Flow

-$230,000.00

FY 2025 · Annual

Financing Cash Flow

$13.38M

FY 2025 · Annual

+147.0% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(203.67M)9.35M(29.73M)(80.94M)(65.78M)
Depreciation & Amortization1.19M1.53M2.96M3.54M3.03M
Deferred Income Tax00000
Stock-Based Compensation28.92M30.61M34.65M37.99M25.41M
Change in Working Capital32.63M(12.56M)7.38M(20.81M)(39.2M)
Accounts Receivables(1.24M)603K(29.3M)28.09M(1.59M)
Inventory00000
Accounts Payables(769K)(3.11M)(2.24M)1.92M(2.96M)
Other Working Capital34.64M(10.05M)38.92M(50.81M)(34.65M)
Other Non-Cash Items5.9M3.06M(33.36M)471K2.28M
Operating Cash Flow(135.04M)31.99M(18.1M)(59.75M)(74.27M)
Capital Expenditures(3.41M)(7.73M)(2.9M)(648K)(230K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(3.41M)(7.73M)(2.9M)(648K)(230K)
Debt Repayment46.6M(5M)(27.36M)00
Common Stock Issued515K411K609K682K13.38M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities902K1.73M2.67M4.74M0
Financing Cash Flow48.02M(2.86M)(24.09M)5.42M13.38M
Effect of Forex Changes00000
Net Change in Cash(90.43M)21.41M(45.09M)(54.98M)(61.12M)
Free Cash Flow(138.45M)24.27M(21M)(60.4M)(74.27M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$65.8M
+ D&A$3.0M
+ Stock-Based Comp$25.4M
+ Deferred Tax$0
- Working Capital-$39.2M
+ Other Non-Cash$2.3M
= Operating Cash Flow-$74.3M
- Capex-$230.0K
= Free Cash Flow-$74.3M

Analysis

FY2025 free cash flow is -$74.3M. FCF conversion is 112.9% of net income. Operating cash flow was -$74.3M, with capex of -$230.0K. The largest bridge item is Working Capital at -$39.2M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 5, 2026
SC 13G/ASC 13G/A filingOct 29, 2026
SC 13G/ASC 13G/A filingOct 7, 2026

Does ARCT generate free cash flow?

Arcturus Therapeutics Holdings Inc. (ARCT) generated -$74.27M of free cash flow in fiscal 2025.

How much operating cash flow does ARCT produce?

Operating cash flow was -$74.27M, before capital expenditures of $230,000.00.